OncLive TV

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

Christine Sam, MD, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 pandemic​.

Andrew B. Nixon, PhD, ​MBA, discusses the role of immunohistochemistry and multiplex polymerase chain reactions tests in detecting microsatellite instability–high tumors.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Alan P. Z. Skarbnik, discusses ongoing research with PI3​K inhibitors in follicular lymphoma. 

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.